PCV26 THE COST-EFFECTIVENESS OF EXTENDED ANTITHROMBOTIC PROPHYLAXIS FOLLOWING TOTAL HIP ARTHROPLASTY  by Skedgel, CD et al.
693Abstracts
preferred (for all groups) followed by buproprion. CONCLU-
SIONS: Smoking cessation is a very cost-effective intervention
for primary prevention of CVD and should be offered ﬁrst to the
smoking populations, before other interventions are considered.
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OBJECTIVES: To compare the cost-effectiveness of extended
antithrombotic prophylaxis using low-molecular-weight heparin
(LMWH), warfarin or aspirin with no extended prophylaxis fol-
lowing total hip arthroplasty in terms of incremental cost per life
year gained. METHODS: Health beneﬁts of extended antithrom-
botic prophylaxis, measured as the reduction in symptomatic
venous thromboembolic (VTE) events and deaths for each treat-
ment alternative, were determined through a meta-analysis of the
literature. Potential years of life lost per VTE death was based
on mean life years remaining for the age distribution of all
patients undergoing total hip arthroplasty in Canada in 2003.
Costs included retail drug costs, administration and monitoring
costs of extended prophylaxis and costs of diagnosing and man-
aging VTE or bleeding events developing within three months of
surgery. The economic analysis used probabilistic modeling
structured around a decision tree characterizing extended pro-
phylaxis choices following total hip arthroplasty. RESULTS: No
studies reported a statistically signiﬁcant effect for aspirin so it
was excluded from the reference scenario. The reference scenario
assumes 50 percent of LMWH and warfarin patients require
home visits for injections or INR monitoring. Probabilistic sim-
ulations found positive life years (LY) gained in the LMWH and
warfarin cohorts relative to no extended prophylaxis (LMWH =
6.9LY gained per 1000 treated; warfarin = 5.5/1000). Net treat-
ment costs were highest in the LMWH cohort at US$742,983
per 1000. LMWH costs were extremely sensitive to the propor-
tion of the cohort receiving home care. Net costs with warfarin
were US$70,540 per 1000 and were much less sensitive to home
visit proportions. The incremental cost-effectiveness ratio (ICER)
of warfarin relative to no further prophylaxis is US$12,778 per
LY gained, while LMWH relative to warfarin is US$475,159.
CONCLUSIONS: The cost-effectiveness of warfarin is quite
favourable relative to generally accepted thresholds. LMWH is
beyond what would be considered cost-effective, even at the
lowest home care proportions.
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OBJECTIVES: To evaluate short (12 months) and long term
cost-effectiveness (CE) of smoking cessation therapies
(willpower, physician advice, nicotine replacement therapies
[NRT/inhaler/patch/gum/tablets/spray] and bupropion [BUP]) in
Finland. METHODS: A decision analytic model was constructed
and analysed from societal viewpoint. Costs included direct
costs. Drug prices were retail prices excluding taxes. Drug dosing
followed recommendations. Prescription medicine treatments
(Rx; NRT/spray, BUP) included the cost of 2 physician visits.
Adverse event incidence was assumed 1% in pharmacotherapies.
Short term effectiveness (probability to quit) was estimated from
those studies included in Cochrane reviews of smoking cessation
that fulﬁlled the inclusion criteria (12 months of continuous
abstinence; OTC: level of support low; Rx: level of support low
or high, no group therapy) using Mantel-Haenszel weights.
Long-term effectiveness (life years saved, LYS) was estimated
from age speciﬁc differences in life expectancies between smokers
and quitters. RESULTS: In the short-term BUP dominated all
pharmacotherapies (NRTs), and its cost/quitter was the lowest
(1167€), disregarding willpower. The incremental cost/quitter
was 1060–1220€ compared to non-pharmacotherapies. In the
long term, BUP cost/LYS was the lowest (365€). After 3% dis-
counting of health beneﬁts (LYS) BUP cost/LYS was 898€. The
BUP incremental cost/LYS as compared to non-pharmacothera-
pies was 330–380€ (discounted 820–940€). Sensitivity analyses
(effectiveness, adverse events) did not produce changes in BUP’s
positioning among cessation therapies. CONCLUSIONS: In
Finland, BUP is a cost-effective alternative in smoking cessation
in short and long-term compared to many other health care 
interventions.
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OBJECTIVES: Ramipril may prevent cardiovascular death,
myocardial infarction, and stroke in patients without evidence
of left ventricular dysfunction or heart failure who are at high
risk for cardiovascular events. In the present study, we assessed
the cost-effectiveness of ramipril in patients with an increased
risk of cardiovascular events from a third-party payer’s perspec-
tive in Switzerland. In addition, the cost-effectiveness of ramipril
in the subgroup of diabetic patients was assessed. METHODS:
We developed a decision analytic cost-effectiveness model to 
estimate the incremental costs (in 2001 Swiss Francs [CHF]),
incremental effects (in terms of life-years gained [LYG]) and
incremental cost-effectiveness (CHF/LYG) of ramipril versus
placebo. Clinical input parameters were derived from the Heart
Outcomes Prevention Evaluation (HOPE) study. Cost data were
extracted from the literature. Deterministic sensitivity analysis
was used to assess the impact of varying the input parameters
on the cost-effectiveness of the intervention. In addition, ﬁrst-
order Monte Carlo simulation was used to capture patient-to-
patient variability, presented as cost-effectiveness acceptability
curves. RESULTS: The incremental cost-effectiveness ratio of
ramipril versus placebo was CHF 6005 per life-year gained in
the base case analysis. In diabetic patients the cost-effectiveness
ratio was CHF 3790 per life-year gained. Varying the price of
ramipril in a deterministic sensitivity analysis only had a mod-
erate impact on the cost-effectiveness ratio in the overall popu-
lation (range: CHF 3652–15,418/LYG) as well as in diabetic
patients (range: CHF 2370–9468/LYG). CONCLUSIONS:
Ramipril in patients at high risk for cardiovascular events 
represents an efﬁcient use of scarce health care resources in
Switzerland and is cost-effective under reasonable assumptions.
Ramipril is even more cost-effective in the subgroup of diabetic
patients.
